Status:
NOT_YET_RECRUITING
Study on the Relationship Between Opioid Drugs and the Therapeutic Efficacy of Immunotherapy
Lead Sponsor:
Hubei Cancer Hospital
Collaborating Sponsors:
Cancer Hospital Chinese Academy of Medical Science
Conditions:
Pain Management
Immune Checkpoint Inhibitor
Eligibility:
All Genders
18-80 years
Brief Summary
Relationship between pain and the efficacy of immunotherapy: Does the degree of pain control affect the therapeutic efficacy of ICIs? Does the use of opioid drugs independently affect the efficacy of ...
Eligibility Criteria
Inclusion
- Aged ≥ 18 years; Histologically confirmed advanced NSCLC (Stage IIIb-IV); Need to receive ICIs treatment; Accompanied by moderate or severe pain (NRS score ≥ 4); Need to use opioid drugs for pain management; Able to understand and sign the informed consent form.
Exclusion
- Suffering from severe dysfunction of important organs such as heart, liver, and kidney; Suffering from mental illness or receiving treatment with psychotropic drugs; Pregnant or lactating women; Participating in other clinical trials; Allergic to opioid drugs.
Key Trial Info
Start Date :
September 17 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2027
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT07188857
Start Date
September 17 2025
End Date
October 1 2027
Last Update
September 23 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.